Bedrijfsoverzicht
Organigram Global Inc. is a specialized entity within the healthcare sector, specifically operating in the drug manufacturing industry for specialty and generic pharmaceuticals, with a primary focus on the production and sale of cannabis and cannabis-derived products in Canada. The company's portfolio encompasses a wide array of medical and recreational cannabis offerings, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, concentrates, and adult-use recreational cannabis. This operational scope positions the organization as a significant player in a regulated industry that bridges medical necessity with consumer wellness markets. As of the latest data, the company commands a market capitalization of $193.05M and generates annual revenue of $279.99M, supported by a workforce of 1137 employees. These financial figures indicate a substantial operational scale relative to many small-cap peers in the cannabis sector, suggesting a well-established distribution network and production capacity capable of serving both medical and adult-use markets simultaneously.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $279.99M with a corresponding net income of $18.17M and an EBITDA of $5.43M. The gap between the substantial revenue figure and the net income reveals a cost structure where operating expenses, including cost of goods sold and general administrative costs, consume a significant portion of top-line growth before reaching the bottom line. However, the profit margin stands at 6.5%, indicating that the company is ultimately profitable on a bottom-line basis despite the pressure on operating margins. The free cash flow is reported at -$39,607,124, which signifies a period of negative cash generation where capital expenditures and working capital requirements currently exceed operational cash receipts, limiting immediate financial flexibility for aggressive expansion without external financing. The balance sheet reflects a cash position of $8.38M against total debt of $8.45M, resulting in a debt-to-equity ratio of 1.99, which characterizes a moderately leveraged position where debt obligations are roughly equal to liquid cash reserves. The current ratio of 2.73 demonstrates strong short-term liquidity, indicating that the company holds 2.73 times the value of its current liabilities in current assets, providing a comfortable buffer for meeting immediate obligations. Return on equity stands at 4.6% while return on assets is -1.5%, revealing that management effectiveness in generating returns on shareholder capital is positive but modest, whereas the return on assets metric highlights the impact of high asset turnover or leverage in diluting asset-level returns in the current fiscal period.
Waarderingsbeoordeling
The valuation metrics present a complex picture with a trailing P/E ratio of 12.73 contrasted sharply by a forward P/E of 77.78. This significant disparity between the trailing and forward multiples implies that the market is pricing in a substantial expected expansion in earnings per share that has not yet been reflected in historical performance, potentially driven by anticipated regulatory changes or volume growth. The price-to-book ratio is 0.71, which indicates that the company's market price trades at a discount to its book value, suggesting the market may be undervaluing the tangible assets or anticipating future challenges that warrant a lower multiple. Alternative valuation metrics include a price-to-sales ratio of 0.69 and an EV/EBITDA of 44.96, where the low P/S ratio relative to the high EV/EBITDA suggests investors are valuing the revenue stream heavily while discounting current earnings power due to the high debt load or negative cash flow trajectory. The stock's trading range over the last year spans from a low of $1.00 to a high of $2.24, and without a specific current share price provided in the facts, the relative position to the 52-week high and low is defined by this established volatility band. The beta value of 1.87 indicates that the stock exhibits high price volatility, moving approximately 1.87 times more aggressively than the broader market, which introduces significant risk for investors seeking stability.
Growth & Income
Revenue growth year-over-year stands at 48.7%, demonstrating a robust expansion in sales volume or pricing power within the Canadian market. Earnings growth is listed as N/A, which implies that while top-line revenue is accelerating rapidly, the bottom-line earnings are either in a transition phase or do not yet show a consistent year-over-year increase comparable to the revenue trajectory. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the organization reinvests all available earnings back into the business for growth rather than distributing income to shareholders. This reinvestment strategy aligns with the high revenue growth rate, prioritizing market share expansion and product line development over immediate shareholder cash returns. The overall growth and income profile is characterized by aggressive revenue expansion funded by internal operations and external capital, with no reliance on dividend income for investors.